Literature DB >> 15638364

Osteochondral defects of the talus treated by mesenchymal stem cell implantation--early results.

P Jancewicz1, W Dzienis, M Pietruczuk, J Skowroński, M Bielecki.   

Abstract

The purpose of this study was to present early results of talus cartilage defects treatment with autologous mesenchymal stem cells CD34+ implantation technique. Nine (9) patients were treated, due to IV degree chondromalation (by ICRS). The applied standard procedure included: clinical examination, AP and lateral x-ray, MRI, preoperative, as well as during control examination. The surgical procedure consisted of the defect's debridement, harvesting and fixation of the periosteal flap and CD34+ implantation. Clinical results were assessed after 6 months to 3 years by clinical examination, Magee score and MRI. Good and very good clinical results were obtained and confirmed by MRI in 8 cases. In one case, cartilage hypertrophy was noted. There were no delamination and infection signs.

Entities:  

Mesh:

Year:  2004        PMID: 15638364

Source DB:  PubMed          Journal:  Rocz Akad Med Bialymst


  4 in total

1.  Erratum: Commentary: Autologous Peripheral Blood Stem Cells (PBSC) are Safe and Effective in Knee Osteoarthritis.

Authors:  Konstantinos I Papadopoulos; Thana Turajane
Journal:  Front Pharmacol       Date:  2021-04-20       Impact factor: 5.810

2.  Knee Osteochondral Defect Reconstruction With Autologous Bone Grafting and Mesenchymal Cell Transplantation.

Authors:  Piotr Jancewicz; Tomasz Mrozek; Adrian Góralczyk; Piotr Radziwon; Małgorzata Rusak; Joanna Chociej-Stypułkowska; Krzysztof Hermanowicz
Journal:  Arthrosc Tech       Date:  2022-06-08

3.  Peripheral Blood-Derived Stem Cells for the Treatment of Cartilage Injuries: A Systematic Review.

Authors:  Yanlin Zhu; Weili Fu
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22

Review 4.  The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review.

Authors:  You-Rong Chen; Xin Yan; Fu-Zhen Yuan; Jing Ye; Bing-Bing Xu; Zhu-Xing Zhou; Zi-Mu Mao; Jian Guan; Yi-Fan Song; Ze-Wen Sun; Xin-Jie Wang; Ze-Yi Chen; Ding-Yu Wang; Bao-Shi Fan; Meng Yang; Shi-Tang Song; Dong Jiang; Jia-Kuo Yu
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.